In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules.
This study evaluated the antibacterial efficacy of the consumption of cranberry capsules vs. placebo in the urine of healthy volunteers. A first double-blind, randomised, crossover trial involved eight volunteers who had followed three regimens, with or without cranberry, with a wash-out period of at least 6 days between each regimen. Twelve hours after consumption of cranberry or placebo hard capsules, the first urine of the morning was collected. Different Escherichia coli strains were cultured in the urine samples. Urinary antibacterial adhesion activity was measured in vitro using the human T24 epithelial cell-line, and in vivo using the Caenorhabditis elegans killing model. With the in-vitro model, 108 mg of cranberry induced a significant reduction in bacterial adherence to T24 cells as compared with placebo (p <0.001). A significant dose-dependent decrease in bacterial adherence in vitro was noted after the consumption of 108 and 36 mg of cranberry (p <0.001). The in-vivo model confirmed that E. coli strains had a reduced ability to kill C. elegans after growth in the urine of patients who consumed cranberry capsules. Overall, these in-vivo and in-vitro studies suggested that consumption of cranberry juice represents an interesting new strategy to prevent recurrent urinary tract infection.
Lavigne
J-P
JP
Institut National de la Santé et de la Recherche Médicale, ESPRI 26, Université de Montpellier 1, UFR de Médecine, Nîmes, France.
Bourg
G
G
Combescure
C
C
Botto
H
H
Sotto
A
A
D000328:Adult; D000818:Animals; D001422:Bacterial Adhesion / Q000187:drug effects; D017173:Caenorhabditis elegans / Q000382:microbiology*; D002214:Capsules / Q000008:administration & dosage* / Q000494:pharmacology; D002460:Cell Line; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004847:Epithelial Cells / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects / Q000472:pathogenicity; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology*; D029799:Vaccinium macrocarpon / Q000737:chemistry; D018440:beta-Lactam Resistance; D047090:beta-Lactams / Q000494:pharmacology
D002214:Capsules; D047090:beta-Lactams